Cure Mechanics Meet Cayman Capital Call Securitization, May 2026 - An Actual Cure or Delaying the Inevitable? Acceleration Cure Provisions in Enforcement of NAV Facilities

Why It Matters

These clauses balance sponsor flexibility with lender protection, influencing recovery rates and transaction speed in complex private‑equity and infrastructure fund loans.

Key Takeaways

• Acceleration cure lets sponsors inject capital or sell assets before enforcement.
• Lender rights vary: consultation vs consent approvals affect cure plan control.
• Bank account security can be seized immediately; cure provisions usually exclude it.
• Reporting milestones are mandatory; failure triggers lender step‑in or independent bank.
• Well‑designed cure provisions preserve value and reduce costly enforcement risk.

Pulse Analysis

Net asset value (NAV) facilities have become a staple financing tool for private‑equity, infrastructure and second‑aries funds, offering lenders a claim on the portfolio’s underlying assets. Yet enforcement is notoriously slow because collateral often carries transfer restrictions, GP cooperation is required, and regulatory approvals can drag on. In credit‑fund structures the process is relatively straightforward, but in private‑equity and infrastructure deals the web of drag‑along rights, change‑of‑control clauses, and industry‑specific approvals can stall a lender’s ability to realize its security. This environment has driven market participants to negotiate acceleration cure provisions as a way to streamline resolution.

An acceleration cure provision grants the sponsor a predefined period to cure a default by injecting fresh capital or orchestrating an orderly sale of portfolio assets before the lender can accelerate and seize the structural security. The provision’s potency depends on whether lenders retain merely consultation rights—allowing them to comment without veto—or full consent rights, which require lender approval by a simple, super‑majority, or unanimous vote. Importantly, the cure typically does not extend to bank‑account security, which lenders can enforce immediately upon acceleration, preserving a fast‑track recovery channel while the sponsor works on the cure plan.

From a business perspective, a well‑calibrated cure clause can protect both parties: sponsors avoid a forced liquidation that could depress asset values, while lenders secure a credible repayment path that mitigates loss‑given‑default. Success hinges on a detailed monetisation plan, transparent milestone reporting, and clear triggers that allow lenders to step in only on material breaches. Mis‑aligned provisions—such as overly generous consultation rights or ambiguous reporting standards—can erode lender confidence and increase financing costs. Practitioners therefore enlist experienced counsel to draft balanced cure language, ensuring the clause adds value rather than becoming a loophole for delay.